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In Brief
CBR hydroxamidines and CBR pyrazoles
inhibit Gram-negative bacterial RNA
polymerase (RNAP) and exhibit
antibacterial activity against Gram-
negative bacteria. Feng et al. report
crystal structures of CBRs bound to
Escherichia coli RNAP and define
structural, mechanistic, cross-resistance,
and additivity relationships between
CBRs and other RNAP inhibitors.
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CBR hydroxamidines are small-molecule inhibitors
of bacterial RNA polymerase (RNAP) discovered
through high-throughput screening of synthetic-
compound libraries. CBR pyrazoles are structurally
related RNAP inhibitors discovered through scaffold
hopping from CBR hydroxamidines. CBR hydroxa-
midines and pyrazoles selectively inhibit Gram-nega-
tive bacterial RNAP and exhibit selective antibacte-
rial activity against Gram-negative bacteria. Here,
we report crystal structures of the prototype CBR
hydroxamidine, CBR703, and a CBR pyrazole in
complex with E. coli RNAP holoenzyme. In addition,
we define the full resistance determinant for
CBR703, show that the binding site and resistance
determinant for CBR703 do not overlap the binding
sites and resistance determinants of other character-
ized RNAP inhibitors, show that CBR703 exhibits no
or minimal cross-resistance with other characterized
RNAP inhibitors, and show that co-administration of
CBR703 with other RNAP inhibitors results in addi-
tive antibacterial activities. The results set the stage
for structure-based optimization of CBR inhibitors
as antibacterial drugs.
INTRODUCTION
CBR703 is the prototype of the CBR hydroxamidine class of
small-molecule inhibitors of bacterial RNA polymerase (RNAP;
Figure 1A; Li et al., 2001a; Artsimovitch et al., 2003). CBR703
was discovered by the Cumbre division of Tularik by high-
throughput screening of synthetic-compound libraries for novel
small-molecule inhibitors of Escherichia coli RNAP (Artsimovitch
et al., 2003). CBR703 is a relatively small (molecular weight = 280
Da) and relatively simple compound comprising two aromatic
rings, one with a 3-trifluomethyl substituent, and an amidoxime
linker (Figure 1A). The compound inhibits Gram-negative enteric
bacterial RNAP (e.g., E. coli RNAP) but not Gram-positive bacte-
rial RNAP (e.g., Mycobacterium tuberculosis RNAP) or human
RNAP I, II, and III (Figure 1C) and exhibits antibacterial activity
against efflux-deficient strains of Gram-negative enteric bacteria1470 Structure 23, 1470–1481, August 4, 2015 ª2015 Elsevier Ltd Albut does not exhibit cytotoxic activity against mammalian cells in
culture (Figure 1D).
The CBR pyrazole class of small-molecule inhibitors of bacte-
rial RNAP are closely structurally related to CBR hydroxamidines
but contain a cyclic conformational constraint (replacement of
the amidoxime linker by a pyrazole linker, which prevents cis-
trans isomerization; Figure 1B; Li et al., 2001b; Artsimovitch
et al., 2003). CBR pyrazoles were identified by scaffold hopping
from the CBR hydroxamidine scaffold. CBR pyrazoles, like
CBR hydroxamidines, exhibit Gram-negative-enteric-selective
RNAP-inhibitory activity and Gram-negative-enteric-selective
antibacterial activity (Figures 1C and 1D).
CBR hydroxamidines and pyrazoles have been shown to
inhibit both transcription initiation by RNAP and transcription
elongation by RNAP (Artsimovitch et al., 2003; Malinen
et al., 2014). Reaction-step-specific assays suggest that CBR
hydroxamidines and pyrazoles inhibit the translocation step
and/or bond-formation step of the nucleotide-addition cycle
(comprising RNAP translocation, nucleoside triphosphate
(NTP) binding, bond formation, and pyrophosphate release) in
transcription initiation and transcription elongation (Artsimovitch
et al., 2003; Malinen et al., 2014). These properties of CBR hy-
droxamidines and pyrazoles differ from the properties of the
best-known small-molecule inhibitor of bacterial RNAP, rifampin
(Rif), which inhibits solely transcription initiation and which does
so by sterically preventing the extension of short RNA products
(Campbell et al., 2001; Feklistov et al., 2008; Ho et al., 2009).
CBR hydroxamidines and pyrazoles have been shown to
inhibit RNAP derivatives containing amino acid substitutions in
the Rif binding site that confer resistance to Rif, suggesting
that CBR hydroxamidines and pyrazoles inhibit RNAP through
a binding site different from the Rif binding site (Artsimovitch
et al., 2003). Isolation and sequencing of CBR-hydroxamidine-
resistant and CBR-pyrazole-resistant mutants indicates that
CBR hydroxamidines and pyrazoles function through a determi-
nant on RNAP, the ‘‘CBR target,’’ that does not overlap the Rif
binding site and is distant from the RNAP active center (Artsimo-
vitch et al., 2003). The CBR target is located at the N terminus of
the RNAP bridge helix, a long a helix that spans nearly the full
width of RNAP (Artsimovitch et al., 2003). The C-terminal part
of the bridge helix forms one wall of the RNAP active center
and is thought to undergo conformational cycling (bending and
unbending) in each nucleotide-addition cycle in transcription
(Weinzierl, 2010; Hein and Landick, 2010). Accordingly, it is
thought that CBR hydroxamidines and pyrazoles inhibit RNAPl rights reserved
Figure 1. CBR Inhibitors
(A) Structure of the CBR hydroxamidine inhibitor CBR703 (compound of
example 1 of Li et al., 2001a).
(B) Structure of the CBR pyrazole inhibitor CBRP18 (compound of example 18
of Li et al., 2001b).
(C) RNAP-inhibitory activities. IC50: concentration resulting in 50% inhibition.
(D) Growth-inhibitory activities. MIC: minimum inhibitory concentration. Anti-
bacterial activities against Gram-negative enteric bacteria are limited to efflux-
deficient strains (e.g., E. coli D21f2tolC). MICs against wild-type strains (e.g.,
E. coli type strain ATCC 25922) are >50 mg/ml.by binding to the CBR target and allosterically affecting confor-
mational cycling of the bridge helix and/or associated structural
elements (Artsimovitch et al., 2003; Malinen et al., 2014). A struc-
tural model of RNAP bound to a CBR inhibitor has been pro-
posed based on in silico docking (Malinen et al., 2014).
There is an urgent need for new antibacterial drugs effective
against Gram-negative bacteria. However, the potential devel-
opment of CBR hydroxamidines and pyrazoles as Gram-nega-
tive antibacterial drugs has been thwarted by the low potencies
of known CBR hydroxamidines and pyrazoles against wild-
type, efflux-proficient Gram-negative bacterial strains (minimum
inhibitory concentrations [MICs] >50 mg/ml; legend to Figure 1;Structure 23, 1470Zhu et al., 2014), and by the absence of structural information
on RNAP-CBR interactions that could be used to inform and
direct medicinal chemistry efforts to improve potency (Li et al.,
2001a, 2001b; Zhu et al., 2014).
In this work, we report crystal structures of bacterial RNAP
bound to CBR inhibitors, and we show, by analyzing bromine
anomalous diffraction from a bromine-containing CBR inhibitor,
that RNAP binds CBR inhibitors in an orientation opposite to that
predicted by Malinen et al. (2014) based on in silico docking. In
addition, we define the full resistance determinant for a CBR in-
hibitor, show that the binding site and resistance determinant for
the CBR inhibitor do not overlap the binding site and resistance
determinant of previously characterized RNAP inhibitors, show
that the CBR inhibitor does not exhibit cross-resistance with
previously characterized RNAP inhibitors, and show that co-
administration of the CBR inhibitor and other RNAP inhibitors
results in additive antibacterial activities.
RESULTS
Structural Basis of Transcription Inhibition by CBR
Inhibitors
Crystal Structures of E. coli RNAP Holoenzyme in
Complex with CBR Inhibitors
To define the structural basis of transcription inhibition by CBR
inhibitors, we determined crystal structures of E. coli RNAP
holoenzyme in complex with CBR inhibitors. We soaked the
CBR hydroxamidine CBR703 and the CBR pyrazole CBRP18
into pre-formed crystals of E. coli RNAP holoenzyme, collected
X-ray diffraction data, solved structures by molecular replace-
ment, and refined structures (Table 1). The resulting crystal
structures of E. coli RNAP holoenzyme in complex with
CBR703 at 4.2 A˚ resolution and E. coli RNAP holoenzyme in
complex with CBRP18 at 4.0 A˚ resolution are shown in Figures
2A–2C and Figures 2D–2F, respectively.
The structures establish that the CBR hydroxamidine CBR703
and the CBR pyrazole CBRP18 bind to the genetically defined
CBR target located at the N-terminal end of the RNAP bridge he-
lix (Figures 2A, 2B, 2D, and 2E) and bind in the identical binding
location and in the identical binding pose (Figures 2B and 2E).
For each CBR inhibitor, clear electron density features are
observed for each of the two aromatic rings and for the linker
(Figures 2B and 2E).
For the CBR hydroxamidine CBR703, the shape of the elec-
tron density feature indicates that the double bond of the linker
adopts the cis configuration (Figure 2B), as predicted based on
the similarity of RNAP-inhibitory potencies of CBR hydroxami-
dines to those of CBR pyrazoles, in which the double bond is
constrained to a cis configuration by a cyclic conformational
constraint (Li et al., 2001a, 2001b).
For each compound, one of the electron density features cor-
responding to the two aromatic rings is substantially larger than
the other (Figures 2B and 2E). For each compound, we assign
the larger density feature to ring B (which contains an electron-
dense trifluoromethyl substituent). This assignment defines the
orientation of each compound relative to the binding site (orien-
tation as shown in Figures 2B, 2C, 2E, and 2F). The orientation
defined in this manner is opposite to the orientation that was pre-
dicted by Malinen et al. (2014) based on in silico docking.–1481, August 4, 2015 ª2015 Elsevier Ltd All rights reserved 1471
Table 1. Crystallographic Data and Refinement Statistics
Dataset Eco RNAP-CBR703 Eco RNAP-CBRP18 Eco RNAP-CBRH16-Br
Beamline BNL-X29A APS-19-ID APS-19-ID
Space group P212121 P212121 P212121
Resolution range (A˚) 50.00–4.20 (4.27–4.20) 50.00–4.00 (4.07–4.00) 50.00–4.10 (4.17–4.10)
Cell parameters (A˚, ) a = 185.8, b = 205.8, c = 307.5 a = 185.6, b = 204.1, c = 308.0 a = 186.3, b = 205.8, c = 307.6
a = 90.0, b = 90.0, g = 90.0 a = 90.0, b = 90.0, g = 90.0 a = 90.0, b = 90.0, g = 90.0
Completeness 1.000 (1.000) 1.000 (1.000) 1.000 (1.000)
Multiplicity 8.7 (7.8) 14.4 (13.8) 13.2 (13.2)
Mean I/s 15.6 (2.1) 14.6 (2.9) 10.1 (3.8)
Rmerge 0.126 (0.980) 0.176 (0.998) 0.234 (0.761)
Rwork 0.270 0.252 0.241
Rfree 0.296 0.286 0.271
Bond-length rmsd (A˚) 0.004 0.005 0.005
Bond-angle rmsd () 0.913 0.983 0.970
PDB code 4ZH2 4ZH4 4ZH3
Rmsd, root-mean-square deviation.Crystal Structure of E. coli RNAP Holoenzyme in
Complex with a Bromine-Containing CBR Inhibitor
In view of the relatively low resolution of the structures (4.2 A˚ res-
olution and 4.0 A˚), in view of the relatively high degree of symme-
try of the observed electron density features (Figures 2B and 2E),
in view of relatively high degree of symmetry of the compounds
(Figures 1A and 1B), and in view of the conflict between the bind-
ing orientation inferred from our electron density maps and the
binding orientation predicted by Malinen et al. (2014) from
in silico docking, we deemed it imperative to obtain an indepen-
dent experimental confirmation of the binding orientation.
To confirm the binding position and binding orientation of CBR
inhibitors, we synthesized a bromine-containing CBR derivative
and collected X-ray diffraction data, including bromine anoma-
lous diffraction, for crystals of E. coli RNAP holoenzyme in
complex with the bromine-containing CBR derivative (Figure 3;
Table1).WesynthesizedaCBR703derivative containingbromine
at position 3 of ringA and fluorine at position 4 of ringB (CBRH16-
Br; designed based on the structure-activity relationships in Li
et al. (2001a) indicating that bromine at position 3 of ring A is toler-
ated without major loss of RNAP-inhibitory activity and that fluo-
rine at position 4 of ring B enhances RNAP-inhibitory activity;
Figure 3A). CBRH16-Br exhibited essentially full RNAP-inhibitory
activity and essentially full antibacterial activity (Figure 3B).
The RNAP-CBRH16-Br complex exhibited electron density for
CBRH16-Br matching that of the RNAP-CBR703 complex (green
mesh inFigures2Band3D) andexhibiteda singlepeakofbromine
anomalous difference density adjacent to the electron density for
CBRH16-Br in the position expected for a bromine atom at posi-
tion 3 of ring A (Figure 3D). The results unequivocally confirm the
binding position and binding orientation of CBR inhibitors is as
shown in Figure 2 and show that the orientation predicted byMa-
linen et al. (2014) from in silico docking is incorrect.
RNAP-CBR Interactions
TheCBR binding site on RNAP is located at an interface between
the RNAP b subunit and the RNAP b0 subunit (Figures 2B, 2C, 2E,
and 2F). The CBR binding site comprises residues of the RNAP b
subunit region D and D-E spacer and residues of the RNAP b01472 Structure 23, 1470–1481, August 4, 2015 ª2015 Elsevier Ltd Alsubunit F loop and bridge helix (Figure 4; conserved region
nomenclature as in Sweetser et al., 1987; Weinzierl, 2010; and
Hein and Landick, 2010).
The binding site contains two pocket-shaped hydrophobic
subsites, which interact with the two aromatic rings of the CBR
inhibitor (Figures 2B, 2C, 2E, and 2F). The CBR inhibitor inserts
into the two subsites in a manner reminiscent of that in which
an electric plug (two-prong; US) plugs into a socket (Figures
2B, 2C, 2E, and 2F).
The first subsite, subsite A, is centered on the first turn of the
RNAP bridge helix, extending from b0L770 to b0I774. The second
subsite, subsite B, is centered on the second turn of the RNAP
bridge helix, extending from b0I774 to b0H777. Residue b0I774
is shared by the two subsites and forms a wall that separates
the two subsites. This residue wedges between aromatic rings
A and B of the CBR inhibitor, interacting with both rings and
with the connector between the rings.
In subsite A, the side chains of b0L770 and b0I774 stack on
opposite faces of ring A of the CBR inhibitor, the side chain of
b0F773 makes an aromatic-aromatic face-edge interaction with
ring A, the side chain of bY555 makes an aromatic-aromatic
edge-edge interaction with ring A, and the aliphatic portion of
the side chain of bR637 makes van der Waals interaction with
ring A (Figures 2B, 2C, 2E, and 2F).
In subsite B, the side chains of bP552 and b0P750 sandwich ar-
omatic ring B of the CBR inhibitor, the backbone of bG640 and
the side chain of b0I774 make van der Waals interactions with
ring B, and the side chain of b0H777 makes van der Waals inter-
actions with the trifluoromethyl substituent on ring B (Figures 2B,
2C, 2E, and 2F). The portion of subsite B closest to atoms 4 and 5
of aromatic ring B of the CBR inhibitor contains an opening that
affords access to bulk solvent, located in a deep groove formed
between the RNAP b lobe and the RNAP F loop (‘‘b-lobe/F-loop
groove’’; Figures 2C and 2F). This opening affords access to bulk
solvent and accounts for structure-activity relationships in Li
et al. (2001a, 2001b), indicating that long side chains can be
incorporated at atoms 4 and 5 of ring B without loss of RNAP-
inhibitory activity.l rights reserved
Figure 2. Crystal Structures of E. coliRNAPHoloenzyme in Complex
with CBR Inhibitors
(A–C) Data for the CBR hydroxamidine CBR703. (D–F) Data for the CBR
pyrazole CBRP18.
(A and D) Structure of E. coli RNAP holoenzyme in complex with the CBR
inhibitor. Gray ribbon: RNAP core. Yellow ribbon: s70. Violet sphere: active-
center catalytic Mg2+. Green: CBR inhibitor.
(B and E) Contacts between RNAP and the CBR inhibitor (stereodiagram).
Green mesh: NCS-averaged mFo-DFc electron density omit map for the CBR
inhibitor (contoured at 2.5s). Green, red, blue, and cyan: carbon, oxygen,
nitrogen, and fluorine atoms of the CBR inhibitor. Gray ribbons: RNAP. Gray
helical ribbon: RNAP bridge helix (N terminus at right).
(C and F) Schematic summary of inferred contacts between RNAP and
the CBR inhibitor. Red dashed lines: H-bonds. Blue arcs: van der Waals
interactions.
Structure 23, 1470Additional interactions between RNAP and the CBR inhibitor
(including the only H-bonded interactions between RNAP and
the CBR inhibitors) involve the connector between rings A and
B of the CBR inhibitor (Figures 2B, 2C, 2E, and 2F). In the case
of the CBR hydroxamidine CBR703, the side chain hydroxyl of
bS642 is inferred to make H-bonds to the oxygen atom and
one nitrogen atom of the amidoxime connector, the backbone
amide of bS642 is inferred to make an H-bond to the oxygen
atom of the amidoxime connector, and the side chain of b0I755
makes van derWaals interactions with the amidoxime connector
(Figures 2B and 2C). In the case of the CBR pyrazole CBRP18,
the side chain hydroxyl of bS642 is inferred to make an
H-bond to one nitrogen atom of the pyrazole, and the side chain
of b0I755 makes van der Waals interactions with the pyrazole
(Figures 2E and 2F).
Residues of the CBR binding site from RNAP b-subunit region
D and the RNAP b0-subunit bridge helix are conserved in RNAP
from bacteria and RNAP I, II, and III from humans (Figure 4). In
contrast, residues of the CBR binding site from the b0-subunit
F loop are conserved in RNAP from bacteria but are not
conserved in RNAP I, II, and III from humans, and residues of
the CBR binding site from the b-subunit D-E spacer–especially
b residue 642, the residue that forms H-bonds with CBR inhibi-
tors in the structures in Figures 2 and 3–exhibit distinct patterns
of sequence conservation in RNAP from Gram-negative enteric
bacteria (e.g., E. coli, Salmonella typhimurium, Klebsiella
pneumoniae, and Enterobacter cloacae), RNAP from other bac-
teria, and RNAP I, II, and III from humans (Figure 4). These pat-
terns of residue conservation are consistent with, and account
for, the observed selectivity of CBR inhibitors for RNAP from
Gram-negative enteric bacteria (Figure 1B).
Resistance Determinant of CBR703
The CBR target was originally identified by isolating and
sequencing a small collection of CBR703-resistant mutants of
an efflux-deficient strain of E. coli (Artsimovitch et al., 2003).
The collection comprised substitutions at three sites: bP560,
bR637, and bS642 (Artsimovitch et al., 2003).
Here, to provide a comprehensive description of the
resistance determinant for a CBR inhibitor, we isolated and
sequenced a large collection of CBR703-resistant mutants of
an efflux-deficient, outer-membrane-disrupted strain of E. coli
(Figure 5). We performed high-level saturation mutagenesis, tar-
geting all codons for all residues of the RNAP b and b0 subunits
located within 30 A˚ of residues of the RNAP bridge helix and/or
of the catalytic Mg2+ ion of the RNAP active center, and we iso-
lated and sequencedmutants resistant to CBR703.We identified
19 different single-amino-acid substitutions that conferred resis-
tance to CBR703: 12 different substitutions affecting nine sites in
RNAP b subunit, and seven different substitutions affecting five
sites in the RNAP b0 subunit (Figure 5A, column 1, and Figure S1).
The identified resistance sites included the three resistance sites
of Artsimovitch et al. (2003) (bP560, bR637, and bS642) and also
included six new resistance sites in the RNAP b subunit (bV550,
bP552, bQ618, bD654, and bT657) and five new resistance sites
in the RNAP b0 subunit (b0I755, b0Q756, b0T757, b0L770, and
b0I774; Figure 5A, column 1 and Figure S1). The statistics of
the analysis, specifically the isolation of multiple independent
isolates of most resistance substitutions (Figure 5A, column 2),–1481, August 4, 2015 ª2015 Elsevier Ltd All rights reserved 1473
Figure 3. Crystal Structure of E. coli RNAP
Holoenzyme in Complex with a Bromine-
Containing CBR Inhibitor
(A) Synthesis and structure of CBRH16-Br
(derivative of compound of example 16 of Li et al.
(2001a) having bromine at position 3 of ring A). (i),
(CH3CH2)3N/CH2Cl2; 0
C; 1 hr. (ii), PCl5/C2H4Cl2;
70C; 5 hr. (iii), (CH3CH2)3N/NH2OH-HCl/CH3CN;
0C–24C.
(B) RNAP-inhibitory activities of CBRH16-Br.
(C) Growth-inhibitory activities of CBRH16-Br.
(D) Electron density, bromine anomalous differ-
ence density, and atomic model for CBRH16-
Br. Green mesh: NCS-averaged mFo-DFc omit
map for CBRH16-Br (contoured at 2.5s). Pink
mesh: bromine anomalous difference density for
CBRH16-Br (contoured at 4.5s). Other colors and
labels as in Figures 2B and 2E.indicate that the analysis is likely to have identifiedmost, if not all,
potential resistance sites.
Most resistance substitutions in the RNAP b subunit conferred
4-fold resistance to CBR703 (Figure 5A, column 3). Most resis-
tance substitutions in the RNAP b0 subunit conferred 2-fold resis-
tance to CBR703 (Figure 5A, column 3).
When mapped on to the three-dimensional structure of bacte-
rial RNAP, the identified resistance sites form a determinant of
30 A˚320 A˚310 A˚ centered on the CBR target of Artsimo-
vitch et al. (2003) and centered on the crystallographically
defined binding site for CBR inhibitors of this work (Figure 5B).
The identified resistance sites include six RNAP residues that
make direct contacts with CBR703 in the crystal structure of
the RNAP-CBR703 complex (bP552, bR637, bS642, b0I755,
b0L770, and b0I774; Figures 2, 4, 5A, and 5C) and include
five other RNAP residues that contact RNAP residues that, in
turn, contact CBR inhibitors (bV550, bP560, bQ618, bD654,
and b0T757; Figures 5A and 5C).
Relationship between the Binding Site and Resistance
Determinant of CBR703 and the Binding Sites and
Resistance Determinants of Other RNAP Inhibitors
Thebinding site and resistance determinant for CBR inhibitors are
located adjacent to, but do not overlap, the binding site and resis-1474 Structure 23, 1470–1481, August 4, 2015 ª2015 Elsevier Ltd All rights reservedtance determinant for the previously char-
acterizedRNAP inhibitor salinamideA (Sal;
Figures 5Band5C).CBR inhibitors andSal
both interact with the RNAP bridge helix,
but they interact with different segments
of theRNAPbridgehelix (bridgehelix turns
1 and 2 for CBR inhibitors, versus bridge
helix turns 3 and4 for Sal) and they interact
with different, nearly opposite, faces of the
RNAPbridgehelix (Figures5Band5C).We
havepreviouslydesignated theSalbinding
site as the RNAP ‘‘bridge helix cap’’ inhib-
itor binding site (Degen et al., 2014). Here,
we designate the CBR inhibitor binding
site as theRNAP ‘‘bridge helix N terminus’’
inhibitor binding site.The binding site and resistance determinant for CBR inhibitors
is distant from, and does not overlap, the binding sites and resis-
tance determinants for other characterized RNAP inhibitors,
including streptolydigin (Stl; which interacts with the central
and C-terminal segments of the bridge helix), GE23077 (GE;
which interacts with RNAP active center i and i+1 nucleotide-
addition sites), Rif (which interacts with a site along the path of
RNA from the RNAP active center), myxopyronin (Myx; which in-
teracts with the RNAP switch region, SW1/SW2 subregion), and
lipiarmycin (Lpm; which interacts with the RNAP switch region,
SW2/SW3 subregion; Figure 5B).
Theabsenceof overlapbetween thebinding site and resistance
determinant of CBR inhibitors and those of other previously char-
acterizedRNAP inhibitors raises thepossibility thatCBR inhibitors
will not exhibit cross-resistance with previously characterized
RNAP inhibitors. We have tested and validated this possibility
by performing antibacterial susceptibility assays assessing
cross-resistance of CBR703-resistant mutants to Sal, Stl, Rif,
Myx, and Lpm, and assessing cross-resistance of Sal-resistant,
Stl-resistant, GE-resistant, Rif-resistant, Myx-resistant, and
Lpm-resistant mutants to CBR703 (Figures 5A and 6). The results
in columns 4–8 of Figure 5A show that CBR703-resistantmutants
exhibit no or minimal cross-resistance to Sal, Stl, Rif, Myx, and
Lpm. The results in Figure 6 show, reciprocally, that Sal-resistant,
Figure 4. Interactions between RNAP and
CBR Inhibitors: Sequence Alignments
Locations of residues that contact CBR inhibitors
in the sequences of RNAP b subunit (A) and
RNAP b0 subunit (B). Sequence alignments for
the b and b0 subunits of bacterial RNAP (top 24
sequences in each panel) and corresponding
subunits of human RNAP I, RNAP II, and RNAP III
(bottom three sequences in each panel), showing
locations of residues that contact CBR inhibitors
in crystal structures of RNAP-CBR703 and
CBRP18 (red rectangle for residue that makes
H-bonded interactions; black rectangles for res-
idues that make van der Waals interactions;
identities from Figures 2B, 2C, 2E, and 2F),
locations of RNAP structural elements (top row of
black bars; boundaries from Weinzierl, 2010 and
Hein and Landick, 2010), and RNAP conserved
regions (next two rows of black bars; boundaries
from Sweetser et al., 1987 and Lane and Darst,
2010). Species are as follows: E. coli (ECOLI),
Salmonella typhimurium (SALTY), Klebsiella
pneumoniae (KLEP7), Enterococcus cloacae
(ENTCC), Vibrio cholerae (VIBCH), Haemophilus
influenzae (HAEIN), Campylobacter jejuni
(CAMJE), Neisseria gonorrhoeae (NEIG1), Sten-
otrophomonas maltophilia (STPMP), Moraxella
catarrhalis (MORCA), Acinetobacter baumannii
(ACIBC), Pseudomonas aeruginosa (PSEAE),
Staphylococcus aureus (STAAU), Staphylo-
coccus epidermidis (STAEQ), Enterococcus
faecalis (ENTFA), Streptococcus pyogenes
(STRP1), Streptococcus pneumoniae (STRP2),
Clostridium difficile (CDIFF), Mycobacterium
tuberculosis (MYCTU), Mycobacterium avium
(MYCA1), Mycobacterium abscessus (MYCA9),
Thermus thermophilus (THETH), Thermus
aquaticus (THEAQ), Deinococcus radiodurans
(DEIRA), and Homo sapiens (HUMAN).Stl-resistant, GE-resistant, Rif-resistant, Myx-resistant, and
Lpm-resistant mutants exhibit no significant cross-resistance to
CBR703and further show thatmanySal-resistantmutants exhibit
hyper-susceptibility, by factors of two to eight, to CBR703.
The absence of overlap between the binding site of CBR inhib-
itors and those of previously characterized RNAP inhibitorsStructure 23, 1470–1481, August 4, 2015further raises the possibility that CBR
inhibitors and previously characterized
RNAP inhibitors may be able to bind
simultaneously to RNAP and, thus, that
co-administration of a CBR inhibitor with
another RNAP inhibitor may result in addi-
tive or super-additive activity. We have
tested and obtained evidence for this
possibility by performing checkerboard
assays (Horrevorts et al., 1987; White
et al., 1996; Meletiadis et al., 2010) as-
sessing antibacterial activities against
E. coli D21f2tolC of combinations of
CBR703 and Sal, CBR703 and Stl,
CBR703 and Rif, and CBR703 and Myx
(Table 2). The results show that co-admin-istration of CBR703with Sal, Stl, Rif, orMyx yieldsminimum frac-
tional inhibitory concentration indices (FICImin) of 0.6–0.99 and
maximum FICI (FICImax) of 1.1–1.5 (Figure 4D), all of which are
within the ranges of 0.5–1.0 for FICImin and 1.0–4.0 for FICImax
deemed indicative of additive interactions (Table 2; White
et al., 1996; Meletiadis et al., 2010).ª2015 Elsevier Ltd All rights reserved 1475
Figure 5. Relationship between the Binding
Sites and Resistance Determinant of
CBR703 and the Binding Sites and Resis-
tanceDeterminants of Other RNAP Inhibitors
(A) Sequences, isolation statistics, CBR703-
resistance levels, and Sal-, Stl-, Rif-, Myx-,
and Lpm-cross-resistance levels of CBR703-resis-
tant mutants. MICwild-type,CBR703 = 6.25 mg/ml;
MICwild-type,Sal = 0.049 mg/ml; MICwild-type,Stl =
1.56 mg/ml; MICwild-type,Rif = 0.20 mg/ml;
MICwild-type,Myx = 0.20 mg/ml; MICwild-type,Lpm =
1.56 mg/ml.
(B) The CBR703 resistance determinant does not
overlap the resistance determinants of Sal, Rif, Stl,
Myx, and Lpm. Structure of bacterial RNAP (two
orthogonal views; gray ribbons for RNAP; violet
sphere for active-center catalytic Mg2+; PDB:
2CW0), showing sites of substitutions that confer
resistance to CBR703 (blue; Figure 5A; Artsimo-
vitch et al., 2003), Sal (green; Degen et al., 2014), Stl
(yellow; Lisitsyn et al., 1985; Heisler et al., 1993;
Severinov et al., 1993, 1995; Tuske et al., 2005), Rif
(red; Ovchinnikov et al., 1981, 1983; Lisitsyn et al.,
1985; Jin and Gross, 1988; Severinov et al., 1993,
1994; Campbell et al., 2001; Garibyan et al., 2003),
Myx (magenta; Mukhopadhyay et al., 2008; Sri-
vastava et al., 2011), and Lpm (cyan; Ebright, 2005;
Srivastava et al., 2011).
(C) The CBR703 binding site and resistance deter-
minant do not overlap the binding site and resis-
tance determinant of Sal. Stereodiagram. Green
mesh, green sticks, gray ribbons, and gray helical
ribbon: mFo-DFc omit map for CBR703, atomic
model forCBR703,RNAP,andRNAPbridgehelix (N
terminus at left) from the crystal structure of RNAP-
CBR703 (Figures 2A–2C). Blue mesh and blue
sticks: mFo-DFc omit map for Sal and atomic model
for Sal from the crystal structure of RNAP-Sal (PDB:
4MEX). Green surfaces: residues at which sub-
stitutions confer CBR703 resistance. Blue surfaces:
residues at which substitutions confer Sal-resis-
tance. See also Table S1 and Figure S1.The observation that co-administration of CBR703 and other
RNAP inhibitors results in additive antibacterial activity (Table 2)
has two important implications for the potential development
of CBR inhibitors as antibacterial therapeutic agents. First,
combining a CBR inhibitor with another RNAP inhibitor should
increase therapeutic efficacy. Second, combining a CBR inhibi-1476 Structure 23, 1470–1481, August 4, 2015 ª2015 Elsevier Ltd All rights reservedtor with another RNAP inhibitor should
suppress the emergence of spontaneous
resistance (since resistance to a combina-
tion of twocompoundswith different bind-
ing sites requires two mutational hits and
therefore is much rarer than resistance to
one compound with one binding site).
Relationship between the Binding
Site and Resistance Determinant of
CBR703 and the RNAP Active
Center
The CBR binding site and resistance
determinant are distant from the RNAPactive center (30 A˚ from the RNAP active center catalytic Mg2+
ion; blue surface and violet sphere in Figures 2A, 2D, and 5B)
and are also distant from the RNAP channels that bind DNA
and RNA. The position of the CBR binding site and resis-
tance determinant are consistent with the proposal of Artsimo-
vitch et al. (2003) and Malinen et al. (2014) that CBR inhibitors
Figure 6. Absence of Cross-Resistance between CBR703 and Other RNAP Inhibitors
(A) Absence of cross-resistance, and presence of hyper-susceptibility, between Sal-resistant mutants (Degen et al., 2014) and CBR703. Blue: hyper-suscep-
tibility (MIC ratio% 1). MICwild-type,CBR703 = 6.25 mg/ml; MICwild-type,Sal = 0.049 mg/ml.
(B) Absence of cross-resistance between Stl-resistant mutants (Tuske et al., 2005) and CBR703. MICwild-type,Stl = 1.56 mg/ml.
(C) Absence of cross-resistance between GE-resistant mutants (Zhang et al., 2014) and CBR703. MICwild-type,GE = 500 mg/ml.
(D) Absence of cross-resistance between Rif-resistant mutants (Jin and Gross, 1988; Garibyan et al., 2003; Zhang et al., 2014) and CBR703. MICwild-type,Rif =
0.20 mg/ml.
(E) Absence of cross-resistance between Myx-resistant mutants (Mukhopadhyay et al., 2008; Degen et al., 2014) and CBR703. MICwild-type,Myx = 0.20 mg/ml.
(F) Absence of cross-resistance between Lpm-resistant mutants (Ebright, 2005; Degen et al., 2014) and CBR703. MICwild-type,Lpm = 1.56 mg/ml.inhibit RNAP through an allosteric, rather than a direct steric
mechanism.
CBR inhibitors make extensive direct interactions with the
N terminus of the RNAP bridge helix; aromatic rings A and B of
the CBR inhibitor are inserted into the grooves formed by the first
and second turns of the bridge helix in a manner that resembles
insertion of a plug in a socket (Figure 2). The position of the CBR
binding site and resistance determinant and the binding mode of
the CBR inhibitor are consistent with the specific proposal of Art-
simovitch et al. (2003) and Malinen et al. (2014) that CBR inhibi-
tors inhibit RNAP allosterically by interfering with conformational
cycling of the RNAP bridge helix and/or associated RNAP struc-
tural elements.
With respect to the hypothesis that CBR inhibitors may inter-
fere with conformational cycling of the RNAP bridge helix, we
note that, in our crystal structures of E. coli RNAP holoenzyme
bound to CBR inhibitors, the bridge helix exhibits the same
straight, unbent conformation as in E. coli RNAP holoenzyme
in the absence of CBR inhibitors (Figure 7), indicating that CBR
inhibitors bind to and stabilize a straight, unbent conformation
of the bridge helix. We further note that, within the limits of reso-
lution, all three classes of bacterial RNAP inhibitors that haveStructure 23, 1470bridge helix binding sites (CBR inhibitors, Sal, and Stl) bind to
and stabilize the same straight, unbent conformation of the
bridge helix (Figure 7B; Degen et al., 2014; Tuske et al., 2005).
With respect to the hypothesis that CBR inhibitorsmay interfere
with conformational cyclingof anRNAPstructural element associ-
ated with the bridge helix (e.g., the trigger loop, F loop, or b lobe
[Weinzierl, 2010; Hein and Landick, 2010]), we note that CBR in-
hibitors are able to inhibit transcription by an RNAP derivative
that lacks the RNAP trigger loop, indicating that transcription inhi-
bition by CBR inhibitors does not require the RNAP trigger loop
and suggesting that transcription inhibition by CBR inhibitors in-
volves mechanisms that are, at least in part, independent of
trigger-loopconformation (Figure 8).Of the three classes of bacte-
rial RNAP inhibitors that have bridge-helix binding sites (CBR
inhibitors, Sal, and Stl), CBR inhibitors and Sal are able to inhibit
transcriptionbyanRNAPderivative that lacks the trigger loop (Fig-
ure 8; Degen et al., 2014), but Stl is not (Temiakov et al., 2005).
The proximity of the binding sites for CBR inhibitors and Sal
(Figures 5B and 5C), together with the similar bridge-helix con-
formations in crystal structures of RNAP bound to CBR inhibitors
and Sal (Figure 7) and the similar trigger-loop independence of
transcription inhibition by CBR inhibitors and Sal (Figure 8),–1481, August 4, 2015 ª2015 Elsevier Ltd All rights reserved 1477
Figure 7. Relationship between the Binding Site and Resistance
Determinant of CBR703 and the RNAP Active Center: CBR Inhibitors
Interact with a Straight, Unbent State of the RNAP Bridge Helix
(A) Electron density and model for bridge helix in crystal structure of RNAP-
CBR703. Green mesh: mFo-DFc omit map for bridge helix (contoured at 2.5s).
Red ribbon: bridge helix backbone. Green, red, blue, and cyan: CBR703
carbon, oxygen, nitrogen, and fluorine atoms.
(B) Superimposition of bridge helices of crystal structures of E. coli RNAP-
CBR703 (red; unbent BH-HN and BH-HC), RNAP-Sal (black; PDB: 4MEX),
E. coli RNAP (green; PDB: 4MEY), T. thermophilus RNAP (cyan; PDB: 1IW7),
T. thermophilus RPo (yellow; PDB: 4G7H), T. thermophilus transcription
elongation complex (magenta; PDB: 2O5J), and paused T. thermophilus
transcription elongation complex (blue; PDB: 4GZY).
BH-HN: bridge helix N-terminal hinge. BH-HC: bridge helix C-terminal hinge.
Table 2. Additive Interaction of CBR703 with Other Bacterial
RNAP Inhibitors
Antibacterial Agents FICImin FICImax Interaction Type
CBR703 + Sal 0.99 1.5 additive
CBR703 + Stl 0.60 1.1 additive
CBR703 + Rif 0.97 1.4 additive
CBR703 + Myx 0.98 1.4 additivesuggest that the mechanisms of inhibition by CBR inhibitors and
Sal may be similar.
DISCUSSION
The results presented here define the structural basis of tran-
scription inhibition by CBR inhibitors, define comprehensively,
or nearly comprehensively, the resistance determinant for CBR
inhibitors, and define the relationship between the binding sites
and resistance determinants for CBR inhibitors and those for
previously characterized RNAP inhibitors.
The structural information in this work provides a foundation for
structure-based design of novel CBR inhibitors with increased
RNAP-inhibitory and antibacterial potency. The structures sug-
gest strategies to modify CBR inhibitors to: (1) increase potency
specifically against Gram-negative enteric bacterial RNAP
and other bacterial RNAP having Ser or Thr at b position 642
(e.g., RNAP from E. coli, K. pneumoniae, E. cloacae, V. cholerae,
Haemophilus influenzae,C. jejuni, andNeisseria gonorrhoeae; Fig-
ure 4); (2) increase potency specifically against bacterial RNAP
having an apolar amino acid at RNAP b position 642 (e.g., RNAP
from Moraxella catarrhalis, Acinetobacter baumannii, Pseudo-
monas aeruginosa, Enterococcus faecalis,Mycobacterium tuber-
culosis, Mycobacterium avium, and Mycobacterium abscessus;
Figure 4), and (3) to increase potency against any bacterial RNAP.
The structures suggest that potency against Gram-negative
enteric bacterial RNAP and other bacterial RNAP having Ser or
Thr at b position 642 could be increased by replacing the pyra-
zole moiety of a CBR pyrazole with a heterocycle able to form
an additional H-bond with the side-chain hydroxyl of Ser or Thr
at RNAP b residue 642 (Figures 2E and 2F).
The structures suggest that potency against bacterial RNAP
having an apolar amino acid at b position 642 could be increased
by replacing the pyrazole moiety of a CBR pyrazole with a het-
erocycle that positions apolar atoms, rather than polar atoms,
adjacent to the side chain of b residue 642.
The structures suggest that potency against RNAP from most
or all bacterial species could be increased by replacing the pyr-
azole moiety of a CBR pyrazole with a heterocycle able to donate
an H-bond to the backbone carbonyl group of b residue 642 (Fig-
ures 2B, 2C, 2E, and 2F); by incorporating a positively charged
substituent at position 6 of ring B of a CBR inhibitor to enable
a salt bridge with bE641; by appending a side chain with
metal-coordinating functionality at position 4 or position 5 of
ring B to enable metal-ion-mediated interactions with a pair of
adjacent histidine side chains in the b-lobe/F-loop groove
(bH447 of b conserved region C and bH551 of b conserved re-
gion D); by appending a side chain with positively charged func-
tionality at position 4 or position 5 of ring B to enable interactions1478 Structure 23, 1470–1481, August 4, 2015 ª2015 Elsevier Ltd Alwith negatively charged side chains in the b-lobe/F-loop groove
(bD444 and bD446 of region C and bE546 of the region C/D
spacer); or by appending a side chain with aromatic functionality
to the connector between rings A and B to enable interactions
with a hydrophobic pocket formed by the bridge helix and
F loop (b0I755, b0T757, b0I759, b0L770, and b0I774).
We note that we were able to isolate CBR703-resistant mu-
tants in E. coli strain D21f2tolC when we used merodiploid
RNAP subunit genes (i.e., mutant RNAP subunit gene on a
plasmid and corresponding wild-type RNAP subunit gene on
the chromosome; Figure 4), but we were unable to isolate
CBR703-resistant mutants in E. coli strain D21f2tolC when we
used haploid RNAP subunit genes (i.e., mutant RNAP subunit
gene on the chromosome and no corresponding wild-type
RNAP subunit gene; Table S1). The observed spontaneous
resistance rate for CBR703 in E. coli strain D21f2tolC in haploid
was < 13 1012, which was at least two to four orders of magni-
tude less than the spontaneous resistance rates for other
characterized RNAP inhibitors (Table S1). We attribute the low
observed spontaneous resistance rate to high fitness costs,
and large growth defects, for CBR703-resistant mutants in
E. coli strain D21f2tolC in haploid.
The ability to perform structure-based design of improved
CBR inhibitors (made possible by the structural studies in thisl rights reserved
Figure 8. Relationship between the Binding Site and Resistance
Determinant of CBR703 and the RNAP Active Center: Transcription
Inhibition by CBR703 Does Not Require the RNAP Trigger Loop
Effects of CBR703 on nucleotide addition by an E. coliRNAP derivative lacking
the RNAP trigger loop (DTL RNAP; Temiakov et al., 2005).work), the potential ability to increase antibacterial activity by co-
administering a CBR inhibitor with another RNAP inhibitor, the
potential ability to suppress the emergence of spontaneous
resistance by co-administering a CBR inhibitor with another
RNAP inhibitor, and the apparent low spontaneous resistance
frequencies and high fitness costs of CBR-resistant mutants
make the CBR hydroxamidine and CBR pyrazole chemical
scaffolds attractive chemical scaffolds for antibacterial drug
discovery.
EXPERIMENTAL PROCEDURES
E. coli RNAP
E. coli RNAP s70 holoenzyme, RNAP core enzyme, and DTL RNAP core
enzyme were prepared as in Degen et al. (2014).
RNAP-Inhibitory Activity
Fluorescence-detected RNAP-inhibition assays were performed using the
profluorescent substrate g-[20-(2-benzothiazoyl)-60-hydroxybenzothiazole]-
ATP (BBT-ATP; Niyomrattanakit et al., 2011). Reaction mixtures contained
(20 ml) 0–100 mM test compound, bacterial RNAP holoenzyme (75 nM E. coli
RNAP holoenzyme, or 75 nMMycobacterium tuberculosis RNAP core enzyme
and 300 nMM. tuberculosis sA [prepared as in Srivastava et al., 2011]), 20 nM
DNA fragment containing positions42 to +426 of the lacUV5(ICAP) promoter
(Naryshkin et al., 2001), 25 mMBBT-ATP (Jena Bioscience), 100 mMguanosine
triphosphate, 100 mM uridine triphosphate, and 100 mM cytidine triphosphate,
in transcription buffer (50 mM Tris-HCl [pH 8.0], 100 mM KCl, 10 mM MgCl2,
1mMDTT, 10 mg/ml BSA, 5%methanol, and 5.5% glycerol). Reaction compo-
nents other than DNA and NTPs were pre-incubated for 10 min at 37C. Reac-
tions were carried out by addition of DNA and incubation for 15 min at 37C,
followed by addition of NTPs and incubation for 60 min at 37C. Reactions
were terminated and profluorescent BBT-diphosphate produced during
reactions was hydrolyzed to fluorescent BBT by addition of 1 ml 0.5 M
AMPSO (Sigma-Aldrich) containing 0.5 U calf-intestinal alkaline phosphatase
(New England BioLabs) and incubation for 20 min at 37C. Fluorescence
emission intensities were measured using a GENios Pro microplate reader
(Tecan; excitation wavelength = 415 nm; emission wavelength = 535 nm).
Half-maximal inhibitory concentrations were calculated by non-linear regres-
sion in SigmaPlot (SPSS).
RNAP-inhibitory activities against human RNAP I, II, and III were determined
as in Degen et al. (2014).
Nucleotide addition by DTL RNAP was assayed as in Degen et al. (2014) but
using a reaction time of 2 min at 37C.
Growth-Inhibitory Activity
MICs were determined as in Degen et al. (2014) but using an initial cell density
of 1 3 105 cells/ml.Structure 23, 1470CBR703-Resistant Mutants
CBR703-resistant mutants were isolated and sequenced essentially as
described for Stl-resistant mutants in Tuske et al. (2005). Saturation mutagen-
esis of plasmid pRL706 carrying E. coli rpoB (Severinov et al., 1997) and
plasmid pRL663 carrying E. coli rpoC (Wang et al., 1995) was performed by
use of PCR amplification with doped oligodeoxyribonucleotide primers span-
ning codons within 30 A˚ of residues of the RNAP bridge helix or the RNAP
active center catalytic Mg2+ ion. Mutagenesis reactions were performed using
the QuikChange Site-Directed Mutagenesis Kit (Agilent/Stratagene) with a
doped oligodeoxyribonucleotide primer, a complementary oligodeoxyribonu-
cleotide primer, and pRL706 or pRL663 as template (primers at 75 nM; all other
components at concentrations as specified by the manufacturer). Mutagen-
ized plasmid DNA was introduced by transformation into E. coli XL1-Blue
(Agilent/Stratagene). Transformants (104 cells) were applied to Luria-Bertani
broth (LB)-agar plates (Sambrook and Russell, 2001) containing 200 mg/ml
ampicillin, plates were incubated for 16 hr at 37C, and plasmid DNA was pre-
pared from the pooled resulting colonies. The resulting passagedmutagenized
plasmid DNA was introduced by transformation into E. coli D21f2tolC (Fralick
and Burns-Keliher, 1994). Transformants (104 cells) were applied to LB-agar
plates containing 7 mg/ml CBR703, 200 mg/ml ampicillin, and 1 mM isopropyl
b-D-1-thiogalactopyranoside; and plates were incubated for 16 hr at 37C.
CBR-resistant mutants were identified by the ability to form colonies on this
medium and were confirmed by re-streaking on the same medium. For each
confirmed mutant, the nucleotide sequence of the mutagenized rpoB or
rpoC segment was determined by Sanger sequencing.
Structure Determination
Crystallization, Crystal Soaking, and Cryocooling
Crystallization and crystal handling were performed essentially as in Degen
et al. (2014). Crystallization drops contained 1 ml E. coli RNAP holoenzyme in
10 mM Tris-HCl (pH 7.9), 100 mM NaCl, and 1% glycerol, and 1 ml reservoir
buffer (RB; 100 mM HEPES [pH 7.0], 200 mM CaCl2, and 18% PEG400),
and were equilibrated against 500 ml RB in a vapor-diffusion hanging-drop
tray at 22C. Crystals formed and grew to a final size of 0.2 mm 3 0.2 mm 3
0.2 mm within 1 week. CBR703, CBRP18, and CBRH16-Br were soaked
into crystals by adding 0.2 ml 20 mM of CBR703, CBRP18, orCBRH16-Br
in (2R, 3R)-()-2,3-butanediol to the crystallization drop and incubating
for 30 min at 22C. Crystals were transferred to RB containing 15% (v/v)
(2R, 3R)-()-2,3-butanediol and then flash-cooled with liquid nitrogen.
Data Collection and Reduction
Diffraction data were collected from cryocooled crystals at Brookhaven
National Laboratory (BNL) beamline X29A and Argonne National Laboratory
(ANL) beamline 19ID. Data were processed using HKL2000 (Otwinowski and
Minor, 1997).
Structure Solution and Refinement
The structures ofE. coliRNAP-CBR703, RNAP-CBRP18, andRNAP-CBRH16-
Br were solved bymolecular replacement with AutoMR in Phenix (McCoy et al.,
2007; Adams et al., 2010), using a crystal structure of E. coliRNAP holoenzyme
as the search model (PDB: 4LK1; Bae et al., 2013). Early-stage refinement
included rigid-body refinement of the RNAP molecule, followed by rigid-body
refinement of each subunit of RNAP molecule. Cycles of iterative model build-
ing with Coot (Emsley et al., 2010) and refinement with Phenix (Adams et al.,
2010) were performed. Atomic models of CBR703, CBRP18, and CBRH16-
Br were built into mFo-DFc difference maps, and subsequent cycles of refine-
ment and model building were performed. The final E. coli RNAP-CBR703,
RNAP-CBRP18, and RNAP-CBRH16-Br models were deposited in the PDB
with accession codes PDB: 4ZH2, 4ZH4, and 4ZH3, respectively (Table 1).
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